Xi'an Kono Chem Co., Ltd., founded in 2014, is a holding enterprise of Hongkong Pioneer Biotech Group. It is an export-oriented manufacturing enterprise supported by the Ministry of Commerce. 

Kono Chem is located in Xi'an, Shaanxi Province, equipped with a number of engineers in pharmaceutical, nutrition, bioengineerting, commited themselves to create products that meeet customers' requirements. At present, Kono's main products cover pharmaceutical, food, cosmetics, scientific research. 

We could give you: 
1.Best quality in your requirement 
2.Competitive price in China market 
3.mature Technical support 
4.Professional logistic support 
All we want is win-win business. Send yr. inquiries, you will get it! 

1. Introduction

Cetyl Tranexamate HCl is a new generation of tranexamic acid, it is also called "TXC", is a unique ester composed of lipid hydrocarbon chains. Its emergence represents a major scientific breakthrough in the control of pigmentation. TXC's unique molecular structure has unprecedented deep penetration into the epidermis, which is 90 times that of traditional acid forms.

2. Main Functions

2.1 Since Cetyl Tranexamate HCl is a kind of tranexammic acid, so it has the functions of the latter, which can brighten the skin by inhibiting the melanin production, lightening pigmentation.

Tranexamic acid and tyrosine have similar chemical structures, which can directly compete with tyrosine, interfere with the catalytic effect of tyrosinase, and reduce the production of melanin. Tranexamic acid also prevents the conversion of plasminogen to plasmin, reduces the release of AA and PGE2, and inhibits melanogenesis. Its mechanism is showed in the figure below.

2.2 Tranexamic acid is also a serine protease inhibitor, which may inhibit melanin transport through the PAR2 signaling pathway.

2.3 Studies have shown that tranexamic acid, as a plasmin inhibitor, can directly inhibit angiogenesis and also inhibit the formation of new blood vessels induced by fibroblast growth factor. Another study showed that 10 female patients with chloasma received 2% tranexamic acid externally for 12 weeks. Skin pathology and immunohistochemical analysis showed that the number of blood vessels in and around the lesions of chloasma decreased, and the growth of vascular endothelial cells. Factor (VEGF) and endothelin-1 (ET-1) expression was down-regulated.

3. Applications

Cetyl Tranexamate HCl is mainly used in cosmetic products, like high-end skin care products, lotions, creams etc.

4. Flow Chart

4-(acetamidomethyl) benzoic acid as starting material→catalytic hydrogenation→-one-step deacetylation transformation→ p-toluenesulfonic acid salify→resin exchange purification→Cetyl Tranexamate HCl 

5. Quality Standard 

6. Method of Analysis 

MOA is available upon request. 

7. Reference Chromatogram